Search | Clinical Trials Finder

Conditions: Type 1 Diabetes (T1D)
Interventions: L. johnsonii Probiotic, Placebo Capsule; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions: Amlexanox, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Type 2
Interventions: Dulce Digital Text Messaging Intervention, CGM Device; Other
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Alzheimer Disease, Dementia
Interventions: NIC5-15, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neurofibromatosis 1
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type1diabetes, Fear of Hypoglycemia
Interventions: Fear of Hypoglycemia, Treatment As Usual; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Mild Traumatic Brain Injury, Concussion
Interventions: Stochastic Galvanic Vestibular Stimulation (sGVS); Device
Lead sponsor: Vivonics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes Mellitus, Periodontal Disease
Interventions: Periodontal Scaling and root planing; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebellar Ataxia
Interventions: Reach training with visual feedback; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 22 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Megestrol Acetate; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 152
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 119 more

Conditions: Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Interventions: Human Papillomavirus Vaccine; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2
Interventions: Alglucosidase alfa; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Smoking
Interventions: Cell Phone Survey; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions: Brexpiprazole, OPC-34712, Placebo Oral Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more

Conditions: Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
Interventions: E7 T Cell Receptor (TCR); Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation
Interventions: KT-413; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Louisville, Kentucky • Detroit, Michigan + 3 more

Conditions: Hypercholesterolemia, Hypertension, Depression, Diabetes Mellitus, Type 2
Interventions: Health at Every Size (HAES), Diet (Traditional, moderate energy restriction); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 30 Years to 45 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 2
States / cities: Davis, California

Conditions: Cerebrovascular Accident
Interventions: Conventional hand exercise, MusicGlove, Conventional Arm Exercise, Resonating Arm Exerciser; Other · Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Irvine, California

Conditions: T1DM, Brain Development
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 16 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumor, Adult, NSCLC, CRC
Interventions: D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Fresno, California • Orange, California • San Francisco, California + 4 more

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more

Search by objective public record fields.

Lactobacillus Johnsonii Supplementation in Adults With T1D

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

Enhancing Digitally Delivered Diabetes Education With Real-Time CGM

Development of NIC5-15 in the Treatment of Alzheimer's Disease

Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial

Intervention to Reduce Fear of Hypoglycemia and Optimize Type 1 Diabetes Outcomes

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Advancement of Vestibular Intervention Via Portable Electrical Stimulator (VIPES)

The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes

Retraining Reaching in Cerebellar Ataxia

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Survey of Smokers Treated in the Emergency Department (ED) on Ownership and Usage of Cell Phones

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model

Influence of Timing on Motor Learning

Brain Health and Development With T1DM

Study to Evaluate D-1553 in Subjects With Solid Tumors

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks